ATS Corp Dossier - Source-backed chat

ATS Corp

ATSToronto Stock Exchange

SectorIndustrials

IndustrySpecialty Industrial Machinery

Beta (adjusted)1.18

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $18.05Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $1.8B

Enterprise Value $2.9B

Shares Outstanding 98M diluted

Moat Rating None

Next Earnings Date4 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ATS Corporation is a premier global provider of custom-designed and standardized manufacturing automation solutions. The company is successfully executing a strategic pivot away from lower-margin, highly cyclical transportation (EV) projects toward highly regulated, high-barrier-to-entry markets such as Life Sciences, Food & Beverage, and Energy. Backed by the disciplined execution of the ATS Business Model (ABM), the company is poised for structural margin expansion of 50 to 75 basis points in fiscal 2027, supported by a robust $1.96 billion backlog and strong free cash flow generation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$46.0020%

Prolonged customer capital investment delays in the Life Sciences sector and macroeconomic headwinds in industrial markets lead to a sharper-than-expected decline in Order Bookings, limiting revenue visibility and offsetting restructuring-driven margin gains.

Base CaseCentral scenario

$50.4350%

ATS achieves modest revenue growth in fiscal 2027 as it works through a normalized life sciences backlog and removes $50 million of dilutive transportation revenues. Adjusted earnings from operations margin expands by 50 to 75 basis points, supported by cost realignment and solid execution of the ABM.

Bull CaseUpside scenario

$57.0030%

Accelerated adoption of automation in life sciences (radiopharmaceuticals, medical devices) and nuclear energy, combined with faster-than-expected margin expansion from the transportation segment restructuring, drives adjusted EBITDA margins toward the long-term 15% target ahead of schedule.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strong revenue visibility supported by a robust $1.96 billion Order Backlog, with approximately 80% concentrated in highly regulated markets.
Strategic cost realignment and exit from dilutive transportation divisions expected to expand operating margins by 50 to 75 basis points in fiscal 2027.
Excellent cash flow generation, with fiscal 2026 free cash flow reaching $371.7 million, driving rapid deleveraging to 2.8x net debt to adjusted EBITDA.

Key Investment Risks

Cyclicality and timing of customer capital expenditure budgets, particularly in the dominant Life Sciences segment.
Execution risks associated with the consolidation of transportation-focused divisions and facility rationalization.
Integration risks from future programmatic M&A transactions under the decentralized operating model.

Thesis Invalidation Triggers

A sustained drop in the book-to-bill ratio below 0.90x over multiple consecutive quarters.
Failure to achieve the targeted 50 to 75 basis point margin expansion in fiscal 2027 due to cost overruns or restructuring delays.
Significant cancellations or scope reductions within the $1.1 billion Life Sciences backlog.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.